Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 4716 | 943319-70-8 |
Dose | Unit | Route |
---|---|---|
45 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 14, 2012 | FDA | ARIAD |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute lymphocytic leukaemia recurrent | 215.16 | 22.15 | 49 | 5724 | 1926 | 50597425 |
Philadelphia chromosome positive | 172.95 | 22.15 | 31 | 5742 | 348 | 50599003 |
Chronic myeloid leukaemia recurrent | 120.96 | 22.15 | 21 | 5752 | 193 | 50599158 |
Blast crisis in myelogenous leukaemia | 114.55 | 22.15 | 23 | 5750 | 489 | 50598862 |
Cytogenetic analysis abnormal | 105.92 | 22.15 | 23 | 5750 | 723 | 50598628 |
Neoplasm progression | 97.27 | 22.15 | 53 | 5720 | 29104 | 50570247 |
Dry skin | 92.67 | 22.15 | 59 | 5714 | 43132 | 50556219 |
Drug resistance | 78.93 | 22.15 | 40 | 5733 | 18949 | 50580402 |
Rash | 77.38 | 22.15 | 160 | 5613 | 437311 | 50162040 |
Death | 73.37 | 22.15 | 132 | 5641 | 325247 | 50274104 |
Peripheral arterial occlusive disease | 70.44 | 22.15 | 23 | 5750 | 3514 | 50595837 |
Blast cell crisis | 66.79 | 22.15 | 11 | 5762 | 71 | 50599280 |
Therapeutic response delayed | 61.51 | 22.15 | 14 | 5759 | 547 | 50598804 |
Stem cell transplant | 55.12 | 22.15 | 16 | 5757 | 1652 | 50597699 |
Thrombocytopenia | 54.72 | 22.15 | 70 | 5703 | 127603 | 50471748 |
Cytopenia | 50.14 | 22.15 | 23 | 5750 | 8752 | 50590599 |
Hypertension | 46.58 | 22.15 | 85 | 5688 | 211118 | 50388233 |
Pleural effusion | 41.90 | 22.15 | 49 | 5724 | 81405 | 50517946 |
Leukaemia recurrent | 41.31 | 22.15 | 12 | 5761 | 1242 | 50598109 |
Off label use | 41.25 | 22.15 | 133 | 5640 | 474293 | 50125058 |
Platelet count decreased | 41.21 | 22.15 | 54 | 5719 | 100672 | 50498679 |
Graft versus host disease | 41.09 | 22.15 | 18 | 5755 | 6148 | 50593203 |
Catabolic state | 41.07 | 22.15 | 7 | 5766 | 57 | 50599294 |
Ichthyosis acquired | 38.05 | 22.15 | 5 | 5768 | 3 | 50599348 |
Lipase increased | 35.49 | 22.15 | 18 | 5755 | 8523 | 50590828 |
Pyrexia | 34.27 | 22.15 | 108 | 5665 | 380095 | 50219256 |
Pancytopenia | 32.74 | 22.15 | 44 | 5729 | 83986 | 50515365 |
Product administered to patient of inappropriate age | 32.58 | 22.15 | 12 | 5761 | 2618 | 50596733 |
Chemotherapy | 31.76 | 22.15 | 10 | 5763 | 1359 | 50597992 |
Chronic myeloid leukaemia transformation | 30.93 | 22.15 | 6 | 5767 | 106 | 50599245 |
Central nervous system leukaemia | 30.46 | 22.15 | 6 | 5767 | 115 | 50599236 |
Soft tissue necrosis | 28.23 | 22.15 | 7 | 5766 | 396 | 50598955 |
Ischaemic stroke | 27.42 | 22.15 | 19 | 5754 | 15929 | 50583422 |
Peripheral artery stenosis | 26.34 | 22.15 | 7 | 5766 | 522 | 50598829 |
Philadelphia positive acute lymphocytic leukaemia | 26.09 | 22.15 | 4 | 5769 | 15 | 50599336 |
Pancreatitis | 25.93 | 22.15 | 28 | 5745 | 42586 | 50556765 |
Capillary leak syndrome | 24.81 | 22.15 | 9 | 5764 | 1881 | 50597470 |
Skin exfoliation | 23.89 | 22.15 | 24 | 5749 | 33588 | 50565763 |
Bone pain | 23.58 | 22.15 | 28 | 5745 | 47201 | 50552150 |
Skin wrinkling | 22.79 | 22.15 | 7 | 5766 | 876 | 50598475 |
Graft versus host disease in skin | 22.17 | 22.15 | 9 | 5764 | 2547 | 50596804 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute lymphocytic leukaemia recurrent | 227.90 | 21.34 | 63 | 7357 | 2453 | 29564654 |
Drug resistance | 200.75 | 21.34 | 101 | 7319 | 21439 | 29545668 |
Neoplasm progression | 181.45 | 21.34 | 90 | 7330 | 18522 | 29548585 |
Cytogenetic analysis abnormal | 152.24 | 21.34 | 34 | 7386 | 536 | 29566571 |
Blast crisis in myelogenous leukaemia | 126.34 | 21.34 | 29 | 7391 | 520 | 29566587 |
Chronic myeloid leukaemia recurrent | 114.60 | 21.34 | 22 | 7398 | 155 | 29566952 |
Loss of therapeutic response | 90.10 | 21.34 | 20 | 7400 | 306 | 29566801 |
Philadelphia chromosome positive | 79.53 | 21.34 | 18 | 7402 | 302 | 29566805 |
Blast cell crisis | 68.69 | 21.34 | 13 | 7407 | 84 | 29567023 |
Lipase increased | 65.77 | 21.34 | 35 | 7385 | 8302 | 29558805 |
Autoimmune lymphoproliferative syndrome | 61.72 | 21.34 | 13 | 7407 | 153 | 29566954 |
Drug intolerance | 61.53 | 21.34 | 68 | 7352 | 48311 | 29518796 |
Death | 60.29 | 21.34 | 205 | 7215 | 341879 | 29225228 |
Blast cells present | 57.17 | 21.34 | 15 | 7405 | 476 | 29566631 |
Peripheral arterial occlusive disease | 47.78 | 21.34 | 24 | 7396 | 5052 | 29562055 |
Viral haemorrhagic cystitis | 47.54 | 21.34 | 15 | 7405 | 925 | 29566182 |
Pleural effusion | 47.29 | 21.34 | 73 | 7347 | 71835 | 29495272 |
Chronic myeloid leukaemia transformation | 45.61 | 21.34 | 10 | 7410 | 144 | 29566963 |
Hepatotoxicity | 43.55 | 21.34 | 36 | 7384 | 17831 | 29549276 |
Gallbladder oedema | 42.86 | 21.34 | 10 | 7410 | 193 | 29566914 |
Pancreatitis | 41.26 | 21.34 | 47 | 7373 | 34467 | 29532640 |
Stem cell transplant | 40.01 | 21.34 | 16 | 7404 | 1971 | 29565136 |
Loss of CAR T-cell persistence | 39.78 | 21.34 | 7 | 7413 | 28 | 29567079 |
Cytokine release syndrome | 39.64 | 21.34 | 30 | 7390 | 13089 | 29554018 |
Central nervous system neoplasm | 39.54 | 21.34 | 8 | 7412 | 76 | 29567031 |
Bone marrow transplant | 39.37 | 21.34 | 13 | 7407 | 927 | 29566180 |
Haematopoietic stem cell mobilisation | 39.06 | 21.34 | 9 | 7411 | 164 | 29566943 |
Platelet count decreased | 38.99 | 21.34 | 83 | 7337 | 104589 | 29462518 |
Renal artery stenosis | 36.77 | 21.34 | 15 | 7405 | 1946 | 29565161 |
Thrombocytopenia | 36.15 | 21.34 | 94 | 7326 | 134729 | 29432378 |
Clonal evolution | 35.93 | 21.34 | 8 | 7412 | 124 | 29566983 |
Graft versus host disease | 35.87 | 21.34 | 25 | 7395 | 9603 | 29557504 |
Cytopenia | 35.34 | 21.34 | 25 | 7395 | 9834 | 29557273 |
Central nervous system leukaemia | 35.24 | 21.34 | 9 | 7411 | 256 | 29566851 |
Hepatic calcification | 32.92 | 21.34 | 9 | 7411 | 335 | 29566772 |
Adrenomegaly | 32.59 | 21.34 | 9 | 7411 | 348 | 29566759 |
Acute lymphocytic leukaemia | 32.53 | 21.34 | 15 | 7405 | 2616 | 29564491 |
Metamyelocyte count increased | 31.89 | 21.34 | 9 | 7411 | 377 | 29566730 |
Renal artery stent placement | 30.97 | 21.34 | 5 | 7415 | 10 | 29567097 |
Renal artery angioplasty | 30.97 | 21.34 | 5 | 7415 | 10 | 29567097 |
Costal cartilage fracture | 30.76 | 21.34 | 8 | 7412 | 245 | 29566862 |
Transplant | 30.64 | 21.34 | 10 | 7410 | 687 | 29566420 |
Periarthritis calcarea | 29.85 | 21.34 | 6 | 7414 | 55 | 29567052 |
Post transplant lymphoproliferative disorder | 29.65 | 21.34 | 18 | 7402 | 5475 | 29561632 |
Articular calcification | 29.56 | 21.34 | 6 | 7414 | 58 | 29567049 |
Graft versus host disease in gastrointestinal tract | 29.48 | 21.34 | 15 | 7405 | 3243 | 29563864 |
Dry skin | 28.29 | 21.34 | 32 | 7388 | 23275 | 29543832 |
Immature granulocyte count increased | 28.00 | 21.34 | 6 | 7414 | 77 | 29567030 |
Myelocyte count increased | 27.90 | 21.34 | 8 | 7412 | 355 | 29566752 |
Adrenal cyst | 27.65 | 21.34 | 6 | 7414 | 82 | 29567025 |
Bone pain | 27.06 | 21.34 | 28 | 7392 | 18424 | 29548683 |
Red cell distribution width increased | 26.90 | 21.34 | 16 | 7404 | 4691 | 29562416 |
Epstein-Barr virus infection | 26.55 | 21.34 | 18 | 7402 | 6611 | 29560496 |
Off label use | 26.15 | 21.34 | 146 | 7274 | 300654 | 29266453 |
Hypertension | 25.96 | 21.34 | 76 | 7344 | 116538 | 29450569 |
Gastrointestinal wall thickening | 25.60 | 21.34 | 10 | 7410 | 1158 | 29565949 |
Bone neoplasm | 25.41 | 21.34 | 7 | 7413 | 268 | 29566839 |
Treatment failure | 24.94 | 21.34 | 38 | 7382 | 36901 | 29530206 |
Peripheral vascular disorder | 24.74 | 21.34 | 15 | 7405 | 4552 | 29562555 |
Diaphragmatic disorder | 23.64 | 21.34 | 9 | 7411 | 973 | 29566134 |
Graft versus host disease in skin | 23.35 | 21.34 | 13 | 7407 | 3366 | 29563741 |
Monocyte count decreased | 22.66 | 21.34 | 9 | 7411 | 1089 | 29566018 |
Activated partial thromboplastin time prolonged | 21.84 | 21.34 | 17 | 7403 | 7725 | 29559382 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute lymphocytic leukaemia recurrent | 321.20 | 20.16 | 83 | 10242 | 3943 | 64484464 |
Drug resistance | 196.84 | 20.16 | 101 | 10224 | 35001 | 64453406 |
Philadelphia chromosome positive | 182.42 | 20.16 | 37 | 10288 | 580 | 64487827 |
Blast crisis in myelogenous leukaemia | 172.43 | 20.16 | 37 | 10288 | 772 | 64487635 |
Neoplasm progression | 160.56 | 20.16 | 93 | 10232 | 40871 | 64447536 |
Cytogenetic analysis abnormal | 122.54 | 20.16 | 29 | 10296 | 952 | 64487455 |
Chronic myeloid leukaemia recurrent | 120.12 | 20.16 | 23 | 10302 | 263 | 64488144 |
Peripheral arterial occlusive disease | 97.16 | 20.16 | 38 | 10287 | 6949 | 64481458 |
Lipase increased | 85.20 | 20.16 | 43 | 10282 | 14359 | 64474048 |
Platelet count decreased | 83.95 | 20.16 | 118 | 10207 | 167593 | 64320814 |
Pleural effusion | 80.22 | 20.16 | 100 | 10225 | 126459 | 64361948 |
Dry skin | 75.92 | 20.16 | 64 | 10261 | 51097 | 64437310 |
Blast cell crisis | 75.38 | 20.16 | 14 | 10311 | 134 | 64488273 |
Stem cell transplant | 70.68 | 20.16 | 25 | 10300 | 3456 | 64484951 |
Thrombocytopenia | 68.68 | 20.16 | 126 | 10199 | 223675 | 64264732 |
Autoimmune lymphoproliferative syndrome | 66.14 | 20.16 | 13 | 10312 | 172 | 64488235 |
Death | 64.40 | 20.16 | 196 | 10129 | 482509 | 64005898 |
Rash | 60.02 | 20.16 | 185 | 10140 | 458364 | 64030043 |
Hypertension | 59.17 | 20.16 | 129 | 10196 | 259132 | 64229275 |
Cytopenia | 57.59 | 20.16 | 34 | 10291 | 15437 | 64472970 |
Renal artery stenosis | 55.29 | 20.16 | 20 | 10305 | 2949 | 64485458 |
Loss of therapeutic response | 54.84 | 20.16 | 12 | 10313 | 275 | 64488132 |
Cytokine release syndrome | 50.67 | 20.16 | 35 | 10290 | 20794 | 64467613 |
Therapeutic response delayed | 50.50 | 20.16 | 14 | 10311 | 868 | 64487539 |
Graft versus host disease | 50.48 | 20.16 | 30 | 10295 | 13783 | 64474624 |
Bone marrow transplant | 49.53 | 20.16 | 15 | 10310 | 1272 | 64487135 |
Central nervous system leukaemia | 46.10 | 20.16 | 11 | 10314 | 374 | 64488033 |
Viral haemorrhagic cystitis | 46 | 20.16 | 15 | 10310 | 1620 | 64486787 |
Off label use | 44.97 | 20.16 | 210 | 10115 | 632596 | 63855811 |
Product administered to patient of inappropriate age | 43.51 | 20.16 | 19 | 10306 | 4582 | 64483825 |
Neutrophil count decreased | 42.60 | 20.16 | 57 | 10268 | 77139 | 64411268 |
Peripheral artery stenosis | 41.90 | 20.16 | 13 | 10312 | 1196 | 64487211 |
Adrenomegaly | 41.11 | 20.16 | 10 | 10315 | 369 | 64488038 |
Haematopoietic stem cell mobilisation | 41.09 | 20.16 | 9 | 10316 | 207 | 64488200 |
Clonal evolution | 40.61 | 20.16 | 9 | 10316 | 219 | 64488188 |
Chronic myeloid leukaemia transformation | 40.08 | 20.16 | 9 | 10316 | 233 | 64488174 |
Loss of CAR T-cell persistence | 36.79 | 20.16 | 6 | 10319 | 24 | 64488383 |
Hepatic calcification | 36.42 | 20.16 | 9 | 10316 | 355 | 64488052 |
Hepatotoxicity | 36.15 | 20.16 | 38 | 10287 | 39924 | 64448483 |
Central nervous system neoplasm | 35.58 | 20.16 | 7 | 10318 | 93 | 64488314 |
Catabolic state | 35.58 | 20.16 | 7 | 10318 | 93 | 64488314 |
Costal cartilage fracture | 34.27 | 20.16 | 8 | 10317 | 247 | 64488160 |
Renal artery angioplasty | 33.21 | 20.16 | 5 | 10320 | 10 | 64488397 |
Ichthyosis acquired | 33.21 | 20.16 | 5 | 10320 | 10 | 64488397 |
Blast cells present | 33.16 | 20.16 | 10 | 10315 | 836 | 64487571 |
Amylase increased | 32.71 | 20.16 | 20 | 10305 | 9665 | 64478742 |
Periarthritis calcarea | 32.54 | 20.16 | 6 | 10319 | 55 | 64488352 |
Philadelphia positive acute lymphocytic leukaemia | 32.16 | 20.16 | 6 | 10319 | 59 | 64488348 |
Metamyelocyte count increased | 31.54 | 20.16 | 9 | 10316 | 620 | 64487787 |
Pancytopenia | 31.14 | 20.16 | 70 | 10255 | 143239 | 64345168 |
Hepatic function abnormal | 30.26 | 20.16 | 44 | 10281 | 64269 | 64424138 |
Adrenal cyst | 30.01 | 20.16 | 6 | 10319 | 87 | 64488320 |
Articular calcification | 29.58 | 20.16 | 6 | 10319 | 94 | 64488313 |
Renal artery stent placement | 29.27 | 20.16 | 5 | 10320 | 28 | 64488379 |
Skin exfoliation | 29.24 | 20.16 | 36 | 10289 | 44849 | 64443558 |
Pyrexia | 28.95 | 20.16 | 170 | 10155 | 558474 | 63929933 |
Leukaemia recurrent | 28.79 | 20.16 | 12 | 10313 | 2582 | 64485825 |
Acute lymphocytic leukaemia | 28.65 | 20.16 | 14 | 10311 | 4357 | 64484050 |
Carotid artery stenosis | 28.37 | 20.16 | 17 | 10308 | 7924 | 64480483 |
Pancreatitis | 28.36 | 20.16 | 41 | 10284 | 59566 | 64428841 |
Chronic graft versus host disease | 26.57 | 20.16 | 15 | 10310 | 6261 | 64482146 |
Neutropenia | 26.11 | 20.16 | 91 | 10234 | 239533 | 64248874 |
Liver disorder | 25.83 | 20.16 | 37 | 10288 | 53314 | 64435093 |
Epstein-Barr virus infection | 25.80 | 20.16 | 19 | 10306 | 12469 | 64475938 |
Myelocyte count increased | 25.70 | 20.16 | 8 | 10317 | 744 | 64487663 |
Post transplant lymphoproliferative disorder | 25.50 | 20.16 | 17 | 10308 | 9527 | 64478880 |
Cerebral infarction | 25.26 | 20.16 | 32 | 10293 | 41012 | 64447395 |
Abdominal pain | 24.56 | 20.16 | 107 | 10218 | 312268 | 64176139 |
Malignant neoplasm progression | 24.36 | 20.16 | 55 | 10270 | 112816 | 64375591 |
Diaphragmatic disorder | 24.29 | 20.16 | 9 | 10316 | 1419 | 64486988 |
Red cell distribution width increased | 23.80 | 20.16 | 18 | 10307 | 12291 | 64476116 |
Febrile neutropenia | 23.76 | 20.16 | 75 | 10250 | 187582 | 64300825 |
Activated partial thromboplastin time prolonged | 23.14 | 20.16 | 18 | 10307 | 12813 | 64475594 |
Bone pain | 23.04 | 20.16 | 33 | 10292 | 47539 | 64440868 |
Fall | 22.74 | 20.16 | 20 | 10305 | 416806 | 64071601 |
Chronic myeloid leukaemia | 22.70 | 20.16 | 11 | 10314 | 3363 | 64485044 |
Ichthyosis | 22.32 | 20.16 | 5 | 10320 | 128 | 64488279 |
Soft tissue necrosis | 22.18 | 20.16 | 7 | 10318 | 681 | 64487726 |
Peripheral vascular disorder | 22.01 | 20.16 | 14 | 10311 | 7247 | 64481160 |
Blast cell count increased | 21.53 | 20.16 | 8 | 10317 | 1271 | 64487136 |
Activated partial thromboplastin time shortened | 21.27 | 20.16 | 7 | 10318 | 778 | 64487629 |
Drug hypersensitivity | 21.03 | 20.16 | 6 | 10319 | 237809 | 64250598 |
Carotid arteriosclerosis | 21.01 | 20.16 | 9 | 10316 | 2070 | 64486337 |
Blood bilirubin increased | 20.96 | 20.16 | 35 | 10290 | 57518 | 64430889 |
White blood cell count decreased | 20.82 | 20.16 | 64 | 10261 | 157773 | 64330634 |
Coronary artery stenosis | 20.76 | 20.16 | 16 | 10309 | 11232 | 64477175 |
Graft versus host disease in skin | 20.55 | 20.16 | 12 | 10313 | 5335 | 64483072 |
Transplant | 20.50 | 20.16 | 7 | 10318 | 871 | 64487536 |
None
Source | Code | Description |
---|---|---|
ATC | L01EA05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS BCR-ABL tyrosine kinase inhibitors |
FDA MoA | N0000175076 | Protein Kinase Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:38637 | tyrosine kinase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
Philadelphia chromosome-positive acute lymphoblastic leukemia | indication | 425688002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.98 | acidic |
pKa2 | 8.49 | Basic |
pKa3 | 5.58 | Basic |
pKa4 | 4.36 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR THE TREATMENT OF LEUKEMIAS |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR THE TREATMENT OF LEUKEMIAS |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR THE TREATMENT OF LEUKEMIAS |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR THE TREATMENT OF LEUKEMIAS |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9029533 | Dec. 22, 2026 | A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192895 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 11192897 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | 9493470 | Dec. 12, 2033 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 18, 2020 | RX | TABLET | ORAL | Dec. 18, 2023 | CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS |
EQ 15MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | Dec. 18, 2023 | CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS |
EQ 30MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | April 23, 2015 | RX | TABLET | ORAL | Dec. 18, 2023 | CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS |
EQ 45MG BASE | ICLUSIG | TAKEDA PHARMS USA | N203469 | Dec. 14, 2012 | RX | TABLET | ORAL | Dec. 18, 2023 | CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Breakpoint cluster region protein | Kinase | INHIBITOR | Kd | 7.30 | CHEMBL | CHEMBL | |||
Tyrosine-protein kinase ABL1 | Kinase | INHIBITOR | IC50 | 9.43 | WOMBAT-PK | CHEMBL | |||
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | IC50 | 7.59 | CHEMBL | |||||
Vascular endothelial growth factor receptor 1 | Kinase | IC50 | 8.43 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.11 | CHEMBL | |||||
Platelet-derived growth factor receptor beta | Kinase | IC50 | 8.92 | CHEMBL | |||||
Mast/stem cell growth factor receptor Kit | Kinase | INHIBITOR | IC50 | 7.90 | WOMBAT-PK | ||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | IC50 | 8.52 | CHEMBL | |||||
Tyrosine-protein kinase Lck | Kinase | Kd | 7.62 | CHEMBL | |||||
Tyrosine-protein kinase Yes | Kinase | Kd | 6.66 | CHEMBL | |||||
Tyrosine-protein kinase Fyn | Kinase | Kd | 7.44 | CHEMBL | |||||
Ephrin type-A receptor 2 | Kinase | Kd | 7.57 | CHEMBL | |||||
Serine/threonine-protein kinase B-raf | Kinase | Kd | 5.92 | CHEMBL | |||||
Receptor-type tyrosine-protein kinase FLT3 | Kinase | IC50 | 9.52 | CHEMBL | |||||
Myosin light chain kinase, smooth muscle | Kinase | Kd | 7 | CHEMBL | |||||
Fibroblast growth factor receptor 3 | Kinase | IC50 | 8.03 | CHEMBL | |||||
Tyrosine-protein kinase HCK | Kinase | Kd | 7.09 | CHEMBL | |||||
Tyrosine-protein kinase JAK1 | Kinase | IC50 | 7.49 | CHEMBL | |||||
Tyrosine-protein kinase JAK2 | Kinase | IC50 | 6.77 | CHEMBL | |||||
Tyrosine-protein kinase CSK | Kinase | INHIBITOR | IC50 | 8.27 | WOMBAT-PK | ||||
Tyrosine-protein kinase Lyn | Kinase | INHIBITOR | IC50 | 9.62 | WOMBAT-PK | ||||
Fibroblast growth factor receptor 1 | Kinase | INHIBITOR | IC50 | 8.66 | WOMBAT-PK | ||||
Abelson tyrosine-protein kinase 2 | Kinase | Kd | 7.70 | CHEMBL | |||||
Mitogen-activated protein kinase 11 | Kinase | Kd | 6 | CHEMBL | |||||
Ephrin type-A receptor 5 | Kinase | Kd | 8.10 | CHEMBL | |||||
Ephrin type-A receptor 4 | Kinase | Kd | 4.77 | CHEMBL | |||||
Fibroblast growth factor receptor 2 | Kinase | IC50 | 8.89 | CHEMBL | |||||
TRAF2 and NCK-interacting protein kinase | Kinase | Kd | 6.42 | CHEMBL | |||||
Tyrosine-protein kinase Fgr | Kinase | Kd | 7.42 | CHEMBL | |||||
Mitogen-activated protein kinase 14 | Kinase | Kd | 6.81 | CHEMBL | |||||
Tyrosine-protein kinase FRK | Kinase | Kd | 7.03 | CHEMBL | |||||
Cyclin-G-associated kinase | Kinase | Kd | 5.73 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 2 | Kinase | IC50 | 8.17 | CHEMBL | |||||
Cyclin-dependent kinase 16 | Kinase | Kd | 5.76 | CHEMBL | |||||
Mitogen-activated protein kinase 9 | Kinase | Kd | 5.10 | CHEMBL | |||||
Calcium/calmodulin-dependent protein kinase kinase 2 | Kinase | Kd | 5.75 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 7.75 | CHEMBL | |||||
Ephrin type-B receptor 4 | Kinase | Kd | 5.83 | CHEMBL | |||||
TGF-beta receptor type-2 | Kinase | Kd | 5.75 | CHEMBL | |||||
MAP kinase-activated protein kinase 2 | Kinase | Kd | 6.33 | CHEMBL | |||||
Tyrosine-protein kinase BTK | Kinase | Kd | 5.74 | CHEMBL | |||||
Ephrin type-B receptor 2 | Kinase | Kd | 5.73 | CHEMBL | |||||
Non-receptor tyrosine-protein kinase TNK1 | Kinase | Kd | 7.08 | CHEMBL | |||||
Cyclin-dependent kinase 17 | Kinase | Kd | 6.47 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase MLT | Kinase | Kd | 7.39 | CHEMBL | |||||
Protein-tyrosine kinase 2-beta | Kinase | Kd | 6.53 | CHEMBL | |||||
Maternal embryonic leucine zipper kinase | Kinase | Kd | 5.53 | CHEMBL | |||||
Discoidin domain-containing receptor 2 | Kinase | Kd | 7.06 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 1 | Kinase | Kd | 6.11 | CHEMBL | |||||
cAMP-dependent protein kinase catalytic subunit alpha | Kinase | IC50 | 6.21 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 4 | Kinase | Kd | 6.51 | CHEMBL | |||||
Cyclin-dependent kinase 19 | Kinase | INHIBITOR | Kd | 7.92 | IUPHAR | ||||
Cyclin-dependent kinase 8 | Kinase | INHIBITOR | Kd | 8.17 | IUPHAR | ||||
Ephrin type-A receptor 1 | Kinase | Kd | 5.94 | CHEMBL | |||||
Ephrin type-B receptor 3 | Kinase | Kd | 6.26 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 1 | Kinase | INHIBITOR | IC50 | 7.92 | IUPHAR | ||||
Fibroblast growth factor receptor 4 | Kinase | IC50 | 8.15 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 7.39 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 4 | Kinase | Kd | 5.66 | CHEMBL | |||||
Interleukin-1 receptor-associated kinase 1 | Kinase | Kd | 6.16 | CHEMBL | |||||
Serine/threonine-protein kinase TAO3 | Kinase | Kd | 5.67 | CHEMBL | |||||
Serine/threonine-protein kinase ULK3 | Kinase | Kd | 5.76 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 1 | Kinase | Kd | 6.31 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 5.53 | CHEMBL | |||||
Bcr/Abl fusion protein | Kinase | IC50 | 9.30 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 3 | Kinase | INHIBITOR | Ki | 8.80 | IUPHAR | ||||
Vascular endothelial growth factor receptor 2 | Kinase | INHIBITOR | IC50 | 8.82 | WOMBAT-PK | ||||
ATP-dependent RNA helicase DDX1 | Enzyme | Kd | 7.07 | CHEMBL | |||||
Platelet-derived growth factor receptor alpha | Kinase | INHIBITOR | IC50 | 8.96 | WOMBAT-PK | ||||
Proto-oncogene tyrosine-protein kinase Src | Kinase | IC50 | 9.05 | CHEMBL |
ID | Source |
---|---|
4340891KFS | UNII |
D09950 | KEGG_DRUG |
4032031 | VUID |
N0000186141 | NUI |
1114544-31-8 | SECONDARY_CAS_RN |
4032031 | VANDF |
C2987417 | UMLSCUI |
CHEBI:78543 | CHEBI |
0LI | PDB_CHEM_ID |
CHEMBL1171837 | ChEMBL_ID |
24826799 | PUBCHEM_CID |
DB08901 | DRUGBANK_ID |
CHEMBL2105708 | ChEMBL_ID |
9362 | INN_ID |
C545373 | MESH_SUPPLEMENTAL_RECORD_UI |
5890 | IUPHAR_LIGAND_ID |
1364347 | RXNORM |
196462 | MMSL |
29016 | MMSL |
31534 | MMSL |
d07936 | MMSL |
014797 | NDDF |
014798 | NDDF |
703796003 | SNOMEDCT_US |
703797007 | SNOMEDCT_US |
703798002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-533 | TABLET, FILM COATED | 30 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-533 | TABLET, FILM COATED | 30 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-534 | TABLET, FILM COATED | 45 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-534 | TABLET, FILM COATED | 45 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-535 | TABLET, FILM COATED | 15 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-535 | TABLET, FILM COATED | 15 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-536 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 33 sections |
Iclusig | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-536 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 33 sections |